A strategic collaboration to speed up the development of allogeneic cell therapies

The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s broad portfolio of hematologic and solid tumors.

Published on Fri, 16 Oct 2020 01:26:21 -0400 and brought to you by salesforce json to html